Buchholz, Alexander: “Zirkulierende Thrombozyten im Rahmen der intraarteriellen digitalen Subtraktionsangiographie und der perkutanen transluminalen Angioplastie: Durchflußzytometrische Bestimmung der Aktivierung ex vivo und in vitro“

Literaturverzeichnis

[1] Adelman B, Michelson AD, et al.: "Evaluation of platelet glycoprotein Ib by fluorescence flow cytometry. " Blood 1985; 66(2): 423-427.

[2] Albanese JR, Venditto JA, et al.: "Effects of ionic and nonionic contrast media on in vitro and in vivo platelet activation. " Am J Cardiol 1995; 76(14): 1059-1063.

[3] Andrioli G, Ortolani R, et al.: "Study of platelet adhesion in patients with uncomplicated hypertension. " J Hypertens 1996; 14(10): 1215-1221.

[4] Arnljots B, Dougan P, et al.: "Antithrombotic and platelet activating effects of heparin in prevention of microarterial thrombosis. " Plast Reconstr Surg 1997; 99(4): 1122-1128.

[5] Ault KA, Mitchell JG, et al.: "Analysis of platelets. " In: Laerum OD, Bjerknes R (Hrsg.): Flow cytometry in hematology. London - San Diego - New York; Academic Press, 1992: 153-163.

[6] Ault KA, Rinder HM, et al.: "Correlated measurement of platelet release and aggregation in whole blood. " Cytometry 1989; 10(4): 448-455.

[7] Bassiouny HS, Song RH, et al.: "Low flow enhances platelet activation after acute experimental arterial injury. " J Vasc Surg 1998; 27(5): 910-918.

[8] Brehme S, Riess H, et al.: "Krankheiten der Arterien, Venen und Lymphgefäße - Krankheiten der Arterien. " In: Stobbe H, Baumann G (Hrsg.): Innere Medizin. 7.Aufl. Berlin - Wiesbaden; Ullstein Mosby, 1996: 311-338.

[9] Broijersen A, Hamsten A, et al.: "Platelet activity in vivo in hyperlipoproteinemia - importance of combined hyperlipidemia. " Thromb Haemost 1998; 79(2): 268-275.

[10] Cahill MR, Macey MG, et al.: "Platelet surface activation antigen expression at baseline and during elective angioplasty in patients with mild to moderate coronary artery disease. " Blood Coagul Fibrinolysis 1996; 7(2): 165-168.

[11] Cahill MR, Macey MG, et al.: "Fixation with formaldehyde induces expression of activation dependent platelet membrane glycoproteins, P-Selectin (CD62) and GP 53 (CD63). " Br J Haematol 1993; 84(3): 527-529.


77

[12] Cao J, Rittgers SE: "Particle motion within in vitro models of stenosed internal carotid and left anterior descending coronary arteries. " Ann Biomed Eng 1998; 26(2): 190-199.

[13] Chronos NAF, Goodall AH, et al.: "Profound platelet degranulation is an important side effect of some types of contrast media used in interventional cardiology. " Circulation 1993; 88(5 Pt 1): 2035-2044.

[14] Chronos NAF, Wilson DJ, et al.: "Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of alpha-granules or lysosomes from, human platelets. " Clin Sci (Colch) 1994; 87(5): 575-580.

[15] Colman RW, Hirsh J, et al.: Hemostasis and Thrombosis. 3. Aufl. Philadelphia; J.B. Lippincott Company, 1994.

[16] Coon JS, Weinstein RS: "Specimen preparation, cell measurements, and probes for flow cytometry. " In: Coon JS, Weinstein RS (Hrsg.): Diagnostic flow cytometry. Baltimore - Hong Kong - London; Williams & Wilkins, 1991: 35-43.

[17] Corash L: "Measurement of platelet activation by flourescence-activated flow cytometry. " Blood Cells 1990; 16(1): 97-108.

[18] Corot C, Chronos N, et al.: "In vitro comparison of the effects of contrast media on coagulation and platelet activation. " Blood Coagul Fibrinolysis 1996; 7(6): 602-608.

[19] Creutzig A: "Chronische arterielle Verschlußkrankheit der Extremitäten (AVK). " In: Classen M, Diehl V, Kochsiek K (Hrsg.): Innere Medizin. 3. Aufl. München - Wien - Baltimore; Urban & Schwarzenberg, 1994: 1021-1031.

[20] Davi G, Romano M, et al.: "Increased levels of soluble P-selectin in hypercholesterolemic patients. " Circulation 1998; 97(10): 953-957.

[21] Eckhardt R: "Durchflußzytometrie, eine schnelle und einfache Methode zur Analyse großer Zellzahlen. " Lab Med 1991; 15: 563-569.

[22] Favero C del: "Kontrastmittel: Eine multifaktorielle Betrachtung. " Bracco-Byk Gulden GmbH. Konstanz.

[23] Garrett KO, Pautler SV, et al.: "The inability of low-molecular-weight dextran, aspirin, and prostaglandin E1 to inhibit monolayer platelet adhesion to polyethylene. " J Lab Clin Med 1993; 122(2): 141-148.


78

[24] Gawaz M, Neumann FJ, et al.: "Platelet function in acute myocardial infarction treated with direct angioplasty. " Circulation 1996; 93(2): 229-237.

[25] Gemmell CH, Ramirez SM, et al.: "Platelet activation in whole blood by artificial surfaces: identification of platelet-derived microparticles and activated platelet binding to leucocytes as material-induced activation events. " J Lab Clin Med 1995; 125(2): 276-287.

[26] Goodman SL, Cooper SL, et al.: "Integrin receptors and platelet adhesion to synthetic surfaces. " J Biomed Mater Res 1993; 27(5): 683-695.

[27] Grines CL, Schreiber TL, et al.: "A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty. " J Am Coll Cardiol 1996; 27(6): 1381-1386.

[28] Hamamoto K, Ohga S, et al.: "Cellular distribution of CD63 antigen in platelets and in three megakaryocytic cell lines. " Histochem J 1994; 26(4): 367-375.

[29] Hay KL, Bull BS: "An analysis of platelet activation and aggregation produced by three classes of contrast media. " J Vasc Interv Radiol 1995; 6(2): 211-217.

[30] Hay KL, Bull BS: "Factors influencing the activation of platelets by nonionic contrast medium. " J Vasc Interv Radiol 1996; 7(3): 401-407.

[31] Hendricks P, Brassel F, et al.: "Nichtoperative interventionelle Verfahren - Perkutane transluminale Angioplastie. " In: Alexander K (Hrsg.): Gefäßkrankheiten. München - Wien - Baltimore; Urban & Schwarzenberg, 1993: 389-400.

[32] Henn V, Slupsky JR, et al.: "CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. " Nature 1998; 391(6667): 591-594.

[33] Holme PA, Orvim U, et al.: "Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. " Arterioscler Thromb Vasc Biol 1997; 17(4): 646-653.

[34] Hung J, Lam JYT, et al.: "Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. " Circulation 1995; 92(9): 2432-2436.

[35] Inoue T, Hoshi K, et al.: "Early detection of platelet activation after coronary angioplasty. " Coron Artery Dis 1996; 7(7): 529-534.


79

[36] Ishiwata S, Tukada T, et al.: "Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. " Am Heart J 1997; 133(4): 387-392.

[37] Itoh T, Nakai K, et al.: "Can the risk for acute cardiac events in acute coronary syndrome be indicated by platelet membrane activation marker P-Selectin ? " Coronary Artery Dis 1995; 6(8): 645-650.

[38] Jung SM, Moroi M: "Platelets interact with soluble and insoluble collagens through characteristically different reactions. " J Biol Chem 1998; 273(24): 14827-14837.

[39] Kawano K, Aoki I, et al.: "Human platelet activation by thrombolytic agents: effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression. " Am Heart J 1998; 135(2 Pt 1): 268-271.

[40] Kolarov P, Tschoepe D, et al.: "PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS). " Eur Heart J 1996; 17(8): 1216-1222.

[41] Konstantopoulos K, Chow TW, et al.: "Shear stress-induced binding of von Willebrand factor to platelets. " Biorheology 1997; 34(1): 57-71.

[42] Konstantopoulos K, Wu KK, et al.: "Flow cytometric studies of platelet responses to shear stress in whole blood. " Biorheology 1995; 32(1): 73-93.

[43] Kopp HP, Hopmeier P, et al.: "Concentrations of circulating P-selectin are increased in patients with newly diagnosed insulin-dependent diabetes mellitus. " Exp Clin Endocrinol Diabetes 1998; 106(1): 41-44.

[44] Kowalska MA, Tuszynski GP, et al.: "Plasma lipoproteins mediate platelet adhesion. " Biochem Biophys Res Commun 1990; 172(1): 113-118.

[45] Krause B, Metzler,P: Angewandte Statistik. 1. Aufl. Berlin; Deutscher Verlag der Wissenschaften, 1983.

[46] Laudano AP, Doolittle RF: "Synthetic peptide derivatives that bind fibrinogen and prevent the polymerisation of fibrin monomers. " Proc Natl Acad Sci USA 1978; 75(7): 3085-3089.

[47] Li JM, Podolsky RS, et al.: "Adhesion of activated platelets to venous endothelial cells is mediated via GPIIb/IIIa. " J Surg Res 1996; 61(2): 543-548.


80

[48] Li X, Gabriel DA: "Differences between contrast media in the inhibition of platelet activation by specific platelet agonists. " Acad Radiol 1997; 4(2): 108-114.

[49] Liu Q, Matsueda G, et al.: "The AGDV residues on the gamma chain carboxyl terminus of platelet-bound fibrinogen are needed for platelet aggregation. " Biochim Biophys Acta 1997; 1343(2): 316-326.

[50] Lohse H, Ludwig R: Prüfstatistik. 1. Aufl. Leipzig; VEB Fachbuchverlag Leipzig, 1982.

[51] Loppnow H, Bil R, et al.: "Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. " Blood 1998; 91(1): 134-141.

[52] Mahler F: "Katheterverfahren. " In: Kappert A (Hrsg.): Lehrbuch und Atlas der Angiologie. 10. Aufl. Bern - Stuttgart - Wien; Huber, 1981: 465-485.

[53] Metzelaar MJ, Schuurman HJ, et al.: "Biochemical and immunohistochemical characteristics of CD62 and CD63 monoclonal antibodies. " Virchows Arch B Cell Pathol Incl Mol Pathol 1991; 61(4): 269-277.

[54] Michelson AD, Ellis PA, et al.: "Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or in vivo wound. " Blood 1991; 77(4): 770-779.

[55] Mickelson JK, Lakkis NM, et al.: "Leucocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease ? " J Am Coll Cardiol 1996; 28(2): 345-353.

[56] Minar E, Ehringer H, et al.: "Platelet deposition at angioplasty sites and its relation to restenosis in human iliac and femoropopliteal arteries. " Radiology 1989; 170(3 Pt 1): 767-772.

[57] Minar E, Ehringer H, et al.: "Platelet deposition at angioplasty sites and platelet survival time after PTA in iliac and femoral arteries: investigations with Indium-111-Oxine labelled platelets in patients with ASA-(1.0 g/day)-Therapy. " Thromb Haemost 1987; 58(2): 718-723.

[58] Morse DS, Adams D, et al.: "Platelet and neutrophil activation during cardiac surgical procedures: impact of cardiopulmonary bypass. " Ann Thorac Surg 1998; 65(3): 691-695.

[59] Murakami T, Komiyama Y, et al.: "Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary artery disease. " Eur J Clin Invest 1996; 26(11): 996-1003.


81

[60] Nishibori M, Cham B, et al.: "The protein CD63 is in platelet dense granules, is deficient in a patient with Hermansky-Pudlak Syndrome, and appears identical to granulophysin. " J Clin Invest 1993; 91(4): 1775-1782.

[61] Nurden AT, Nurden P: "A review of the role of platelet membrane glycoproteins in the platelet-vessel wall interaction. " Baillieres Clin Haematol 1993; 6(3): 653-690.

[62] Ostrovsky L, King AJ, et al.: "A juxtacrine mechanism for neutrophil adhesion on platelets involves platelet-activating factor and a selectin-dependent activation process. " Blood 1998; 91(8): 3028-3036.

[63] de Padua Mansur A, Caramelli B, et al.: "Smoking and lipoprotein abnormalities on platelet aggregation in coronary heart disease. " Int J Cardiol 1997; 62(2): 151-154.

[64] Rhodes NP, Kumary TV, et al.: "Influence of wall shear rate on parameters of blood compatibility of intravascular catheters. " Biomaterials 1996; 17(20): 1995-2002.

[65] Rhodes NP, Zuzel M, et al.: "Granule secretion markers on fluid-phase platelets in whole blood perfused through capillary tubing. " J Biomed Mater Res 1994; 28(4): 435-439.

[66] Rieger H: "[Conservative therapy of arterial occlusive disease]. " Herz 1989; 14(1): 1-11.

[67] Rohrer MJ, Kestin AS, et al.: "High-dose heparin suppresses platelet alpha granule secretion. " J Vasc Surg 1992; 15(6): 1000-1009.

[68] Rosenblum WI: "Platelet adhesion and aggregation without endothelial denudation or exposure of basal lamina and/or collagen. " J Vasc Res 1997; 34(6): 409-417.

[69] Roth JJ, Gahtan V, et al.: "Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia. " J Surg Res 1998; 74(1): 11-16.

[70] Ruf A, Patscheke H: "Flow cytometric detection of activated platelets: comparison of determining shape change, fibrinogen binding, and P-Selectin expression. " Semin Thromb Haemost 1995; 21(2): 146-151.

[71] Scharf RE, Tomer A, et al.: "Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. " Arterioscler Thromb 1992; 12(12): 1475-1487.

[72] Schneider DJ, Tracy PB, et al.: "Differential effects of anticoagulants on the activation of platelets ex vivo. " Circulation 1997; 96(9): 2877-2883.


82

[73] Schrör K: "Antiplatelet drugs. A comparative review. " Drugs 1995; 50(1): 7-28.

[74] Schultheiß HP, Tschoepe D, et al.: "Large platelets continue to circulate in an activated state after myocardial infarction. " Eur J Clin Invest 1994; 24(4): 243-247.

[75] Serrano CV Jr, Ramires JA, et al.: "Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. " J Am Coll Cardiol 1997; 29(6): 1276-1283.

[76] Shattil SH: "Why is platelet activation useful for assessing thrombotic risk? What are the advantages and limitations of using flow cytometry to measure platelet activation? " Am J Clin Nutr 1992; 56(4 Suppl): 789-790.

[77] Storm R: Wahrscheinlichkeitsrechnung, mathematische Statistik und statistische Qualitätskontrolle. 7. Aufl. Leipzig; VEB Fachbuchverlag Leipzig, 1979.

[78] Terres W, Lund GK, et al.: "Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions. " Am Heart J 1995; 130(4): 711-716.

[79] Tschoepe D: "Adhesion molecules influencing atherosclerosis. " Diabetes Res Clin Pract 1996; 30(Suppl): 19-24.

[80] Tschoepe D, Driesch E, et al.: "Activated platelets in subjects at increased risk of IDDM. DENIS Study Group. Deutsche Nikotinamid Interventionsstudie. " Diabetologia 1997; 40(5): 573-577.

[81] Tschoepe D, Driesch E, et al.: "Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia. " Diabetes 1995; 44(8): 890-894.

[82] Tschoepe D, Roesen P, et al.: "Platelets in diabetes: the role in the hemostatic regulation in artherosclerosis. " Semin Thromb Hemost 1993; 19(2): 122-128.

[83] Tschoepe D, Schultheiß HP, et al.: "Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. " Circulation 1993; 88(1): 37-42.

[84] Vanhoutte PM: "[Endothelial dysfunction and coronary heart disease. Interaction of endothelium and thrombocytes]. " Schweiz Rundsch Med Prax 1993; 82(42): 1161-1166.


83

[85] Verkleij MW, Morton LF, et al.: "Simple collagen-like peptides support platelet adhesion under static but not under flow conditions: interaction via alpha2beta1 and von willebrand factor with specific sequences in native collagen is a requirement to resist shear forces. " Blood 1998; 91(10): 3808-3816.

[86] Verstraete M, Zoldhelyi P: "Novel antithrombotic drugs in development. " Drugs 1995; 49(6): 856-884.

[87] Wagner HH: "Aortographie und Arteriographie peripherer Gefäße - Methodik. " In: Alexander K (Hrsg.): Gefäßkrankheiten. München - Wien - Baltimore; Urban & Schwarzenberg, 1993: 228-230.

[88] Wheeless, LL Jr.: "Flow instrumentation and data analysis. " In: Coon JS, RS Weinstein (Hrsg.): Diagnostic flow cytometry. Baltimore - Hong Kong - London; Williams & Wilkins, 1991: 17-34.

[89] White SA, Thompson MM, et al.: "Risk factors leading to arterial occlusion following diagnostic arteriography. " Eur J Vasc Endovasc Surg 1995; 10(1): 4-8.

[90] Xiao Z, Theroux P: "Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. " Circulation 1998; 97(3): 251-256.

[91] van Zanten GH, Heijnen HF, et al.: "A fifty percent reduction of platelet surface glycoprotein Ib does not affect platelet adhesion under flow conditions. " Blood 1998; 91(7): 2353-2359.

[92] Zeitler E, Feng G, et al.: "[Results of percutaneous transluminal angioplasty]. " Herz 1989; 14(1): 22-28.


[Titelseite] [Widmung] [Abkürzungsverzeichnis] [1] [2] [3] [4] [5] [6] [Bibliographie] [Danksagung] [Selbständigkeitserklärung] [Lebenslauf]

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.

DiDi DTD Version 1.1
a subset from ETD-ML Version 1.1
Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML - Version erstellt am:
Wed Nov 24 19:17:59 1999